SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Pharmacyclics (PCYC)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
717 42 0 PCYC
Emcee:  Doug Meetmer Type:  Unmoderated
Please also see discussions about PCYC under QLT area.

Pharmacyclics is a company with three products in clinical development
and multiple compounds in preclinical development. Their products are:

Gd-Tex (gadolinium texophyrin), a radiation sensitizer. This product
is in Phase I trials, which are still open for enrollment. They are
studying effects on brain metastases, as well as looking at MDT's
(maximum tolerable dose).

Lu-Tex (lutetium texaphyrin PCI-0123), a light activated drug being
studied for treatment of various cutaneous tumors, including Kaposis
Sarcoma, melanoma, breast CA, and others. It is in Phase I trials,
the interim results of which looked very favorable for both efficacy
and toxicity. In fact, it could be a very important compound when and
if they demonstrate its efficacy in trials, because the drug has a fairly
short half-life, which limits its toxicity.

Gadolite oral suspension, an MRI contrast agent for the GI tract. This
is in Phase III trials and a NDA has been filed.

I believe they will compete in a difficult but very promising market.
The real question will be what , if any, advantages will Lu-Tex
have over products being studied by QLT and PDT. The CEO of PCYC is
Rich Miller who founded IDEC pharmaceuticals and he is supposedly
a very bright guy and whatever he touches seems to work (both
scientifically and for the shareholders).

I am not a stock promoter nor am I a principal of the company,
but I have been watching PCYC for several months and just
bought some shares due to the recent weakness in its stock price, and
because of the potential for its products.

I would love to keep and ongoing discussion about this company.

Doug
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
717Blood. 2015 Apr 2. pii: blood-2015-01-621391. [Epub ahead of print] Selinexor iscaram(o)uche-4/7/2015
716Story about the President of Pharmacyclics being the largest donor to ScientologChris12-1/29/2013
715You were more than right. $60 though?Wayners-7/18/2012
714ok, so over a longish range these guys have been steady. expecting that they wilmarketfriends-2/8/2012
713ok, this might interest some people who have been thinking about PCYC. marketfrmarketfriends-2/6/2012
712PCYC will going up very soon. What do you think??dondon26-5/2/2007
711What about the compassionate conservative panel (CCAC)?rkrw-4/4/2007
710Here's hoping it is accepted and they draw the neutraceuticals panel.keokalani'nui-4/4/2007
709PCYC... I file on you. Pharmacyclics to file cancer drug over FDA protest Wed Akenhott-4/4/2007
708<i>I wonder what this is about.</i> Hmm. Lot of shares short.Steve Lokness-4/3/2007
707I wonder what this is about. If the BoD staged a coup or they dump the texaphrikeokalani'nui-4/3/2007
706I just listened to Cowen and dumped the few shares I bought after the RTF. The keokalani'nui-3/15/2007
705Hi mcbio I do not follow them anymore. Have no insight into what they are doinJohn McCarthy-3/3/2007
704Anyone follow PCYC anymore? I don't have a position but am considering givemcbio-3/3/2007
703Pharmacyclics Announces Presentation and Publication of Preliminary Results EvalJohn McCarthy-12/12/2005
702RE "nice action....." For sure! I seem to remember PCYC crashing froEACarl-3/2/2004
701Nice action today. Message 19869718 MarcJMarcus-3/2/2004
700Any thoughts on the enrollment period for the current Phase 3 SmartTrial. I beGary105-1/21/2004
699It is an interesting case. I would like to know why they saw so "good"Icebrg-1/18/2004
698(editing, here..... Marc, I meant to address this post to you, just to let yoscaram(o)uche-1/18/2004
697Response to motexafin gadolinium and ionizing radiation of experimental rat prosIcebrg-1/16/2004
696Marc >>It just so happens that NSCLC metastasizing to the brain provides Icebrg-1/16/2004
695The CEO's letter to stockholders from the 2003 Annual Report provides a goodJMarcus-1/16/2004
694Erik, for the moment I'm pingponging between here and the Biotech Valuation JMarcus-1/16/2004
693>>Journal of Clinical Oncology>> The big Question is "Why onlyIcebrg-1/16/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):